News Related to B-cell maturation antigen (BCMA)

Related coverage linked through entity extraction aliases.

Meta-analysis Finds High Infection Burden With Teclistamab in Relapsed/Refractory Multiple Myeloma

May 21, 2026

A systematic review and meta-analysis found high infection rates with teclistamab in relapsed/refractory multiple myeloma. Five studies showed pooled infection rates of 56.5% for any grade and 27.6% for grade 3 or higher.

New therapies and testing advances reshape multiple myeloma care

May 06, 2026

New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.